Karyopharm Therapeutics Inc.
KPTI
$8.38
-$0.17-1.99%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -102.20M | -33.13M | -37.25M | -23.46M | -30.78M |
| Total Depreciation and Amortization | 19.00K | 121.00K | 78.00K | 78.00K | 81.00K |
| Total Amortization of Deferred Charges | 2.45M | 2.81M | 2.72M | 2.57M | 2.36M |
| Total Other Non-Cash Items | 82.41M | 10.09M | 5.71M | -16.65M | -6.88M |
| Change in Net Operating Assets | 5.50M | 14.25M | 10.05M | -1.53M | 9.41M |
| Cash from Operations | -11.83M | -5.86M | -18.70M | -38.98M | -25.81M |
| Capital Expenditure | -- | -- | -- | -- | 53.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.00M | 4.81M | 18.29M | 15.29M | 14.74M |
| Cash from Investing | 5.00M | 4.81M | 18.29M | 15.29M | 14.80M |
| Total Debt Issued | 27.25M | -- | -- | -- | 0.00 |
| Total Debt Repaid | -250.00K | -- | -- | -- | -- |
| Issuance of Common Stock | 9.16M | 0.00 | 356.00K | -- | 680.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.46M | -- | -- | -- | 0.00 |
| Cash from Financing | 29.69M | 0.00 | 356.00K | -- | 680.00K |
| Foreign Exchange rate Adjustments | 5.00K | 2.00K | 8.00K | 5.00K | -20.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.87M | -1.05M | -48.00K | -23.69M | -10.35M |